2013
Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial
Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD. Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial. Journal Of Clinical Oncology 2013, 31: 2692-8. PMID: 23752109, DOI: 10.1200/jco.2012.44.1956.Peer-Reviewed Original ResearchConceptsHazard ratioPredictive factorsBreast cancerEarly-stage HER2-positive breast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusOverall survival hazard ratioHER2-positive breast cancerHuman epidermal growth factor receptorHerceptin Adjuvant (HERA) trialYear of trastuzumabIndependent risk factorSurvival hazard ratioAnti-HER2 treatmentBreast cancer outcomesTrial of womenBreast cancer recurrenceSeparate Cox modelsImpact of ageEpidermal growth factor receptorPrediction of benefitAdjuvant trialsGrowth factor receptorHERA trialMedian follow
2006
Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials
Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion On Biological Therapy 2006, 6: 951-962. PMID: 16918262, DOI: 10.1517/14712598.6.9.951.Peer-Reviewed Original ResearchConceptsBreast cancerVascular endothelial growth factor levelsEarly-stage breast cancerYear of trastuzumabHER2/neu geneGrowth factor levelsBreast cancer cellsAdjuvant settingNeoadjuvant trialsOverall survivalRandomised trialsAggressive courseImproved outcomesImmune responseTrastuzumabActivation initiatesFactor levelsHER2 phosphorylationMonoclonal antibodiesNeu geneCancerCancer cellsHER2TrialsAntibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply